Domperidone — sold across India as Domstal and a long list of other brands — does produce a measurable increase in expressed milk in trials, but the effect is modest, the trials are small, and it carries a cardiac warning serious enough that the US Food and Drug Administration cautions that using domperidone to increase milk production or stimulate lactation could cause serious adverse effects. It is not a first step, and it is not a substitute for fixing why milk removal isn't working.
Not medical advice. This article does not tell anyone to start, stop, or change a medicine. If a doctor has prescribed you domperidone, talk to that doctor before changing anything.
The short version
- Pooled randomised trials found a statistically significant relative increase of 74.72% in daily milk production compared with placebo — but that came from only three small trials.
- In mothers pumping for preterm babies, 24-hour volumes on average still remained below the target of 500 mL/day, so the drug narrowed a gap rather than closing it.
- There is currently no evidence that use of domperidone improves breastfeeding outcomes — most trials measured expressed milk in a pump bottle, not how long a baby ended up breastfeeding.
- Domperidone can cause a small increased risk of serious cardiac events, especially at high doses, for longer periods, or when additional risk factors are present.
- The Indian Academy of Pediatrics handles low supply as a feeding problem: more frequent feeds, especially at night, proper attachment to breast, care of painful condition, and building the mother's confidence. No galactagogue drug appears in that treatment list at all.
Why a supply pill gets offered so readily here
Domperidone is everywhere in Indian medicine cabinets. An audit of prescriptions across Indian tertiary care centres found that fixed-dose combinations of domperidone with a proton-pump inhibitor are commonly prescribed in Indian healthcare settings, largely for reflux and nausea. A drug that familiar gets reached for quickly when a new mother says she isn't making enough.
The second reason is that the worry itself is common — and often not matched by the numbers. A cohort study of first-time breastfeeding mothers pointed to a study which showed no significant association between perceived insufficient milk and 24-hour milk production at week 2. A baby who cries a lot, cluster-feeds in the evening, or wakes often reads as "not enough milk" to almost every family, and in a joint household four or five people will say so out loud.
What the trials actually measured
Domperidone works a little, in a narrow setting, for a short time.
| What people assume | What the evidence shows |
|---|---|
| It restores a full milk supply | Volumes rose but stayed short of a full day's supply in preterm studies |
| It's well studied | The pooled analysis rested on three small randomised trials |
| More is better | Two small studies found no significant extra milk at double the dose |
| It fixes breastfeeding | Trials mostly measured pumped volume, not breastfeeding outcomes |
Almost all of the useful data comes from mothers pumping for babies in the NICU, not from mothers feeding a healthy term baby at home. On dose, most published studies used domperidone at 10 mg three times daily for four to ten days, and two small studies found no statistically significant additional increase in milk output at 20 mg three times daily. Doubling up does not double the milk.
The safety signal, in plain terms
Domperidone's problem is the heart, not the baby. On infant exposure the picture is reassuring: infants would probably receive less than 0.1% of the maternal weight-adjusted dosage, even at high maternal doses. The risk sits with the mother.
Regulators abroad have acted on that risk. The FDA has linked domperidone to serious cardiac adverse events including QT prolongation, torsade de pointes, cardiac arrest and sudden death, and published warnings in 2004 and 2012 about cardiac risks with its use to increase lactation. NHS pharmacy guidance sets out who is most exposed: patients at higher risk include those with cardiac disease, severe liver problems, electrolyte imbalances, or taking medicines affecting the QT interval.
The UK went further on the licensed use. After a safety review the drug was restricted to short-term nausea and vomiting, with the adult daily dose capped at 30 mg and treatment at seven days, and domperidone is now contraindicated in people with conditions where cardiac conduction is, or could be, impaired; in people with underlying cardiac diseases such as congestive heart failure; in people receiving other medications known to prolong QT interval or potent CYP3A4 inhibitors; in those with severe hepatic impairment. That last group matters in India, where antifungals and some antibiotics are dispensed freely — a full list of everything you are taking, including anything bought over the counter, belongs in that consultation.
There is a second, less-discussed issue: stopping. Canadian health authorities found an association between abrupt discontinuation or tapering of domperidone used for lactation and psychiatric adverse events, and Canadian labelling warns against doses greater than 30 mg daily for longer than four weeks. That is one more reason this is a conversation with a prescriber, not a decision to make alone at 2 am.
Duration matters in India specifically. The same Indian prescribing audit found that 62% of the domperidone prescriptions it examined had a missing duration. A drug whose risk rises with length of use is a poor candidate for an open-ended prescription.
What good practice looks like before any prescription
The clearest published pathway comes from NHS pharmacy guidance, which says to complete a full assessment to understand the underlying cause of the low milk supply and correct any known problems before considering domperidone. The same guidance notes that ongoing lactation support will be necessary during treatment, and regular review is needed if domperidone is used beyond 7 days.
A clinical viewpoint on the drug puts the sequencing plainly: when all conservative measures have been exhausted and natural augmentation has failed, the use of domperidone may be considered.
What raises supply more reliably
Milk supply answers to milk removal. Generally, the more your baby feeds, the more breast milk you'll produce — and if you're worried your baby is not getting enough, talk to your midwife, health visitor or a breastfeeding specialist as soon as possible. In India that specialist is an IBCLC lactation consultant — most large city hospitals have one attached to the maternity unit, and video consults are easy to book.
Before assuming supply is the problem, check the two markers the IAP uses: milk is adequate if the baby passes urine at least six times a day and gains weight adequately. And the IAP's list of causes is where a good assessment starts: not breastfeeding frequently, poor position, poor attachment, too short or hurried breastfeeds, and breast engorgement or mastitis.
If supply genuinely needs building, the levers are unglamorous. Express your breast milk regularly between feeds to encourage a steady supply. Even in the drug trials the pumping never stopped: the preterm review is explicit that mothers need to maintain pumping to facilitate the autocrine regulatory mechanism.
What about shatavari, fenugreek and the other options?
Herbal galactagogues are the default suggestion in most Indian families, and methi (fenugreek) has the most research behind it. It is still thin: one meta-analysis found fenugreek to have a mild galactogogue effect and unknown safety profile, while another found no good evidence that it is a galactogogue. Traditional foods in normal amounts are a different matter from concentrated capsules — mention either to your doctor.
Metoclopramide, the other prescription option, has weaker evidence than domperidone. A meta-analysis of 8 trials involving 342 lactating women found that metoclopramide increased serum prolactin, but did not increase milk supply.
FAQ
Is domperidone banned in India? No. It is a prescription medicine that remains widely used here — the Indian prescribing audit describes domperidone combinations as commonly prescribed in Indian healthcare settings. Its status differs from country to country, and using it for milk supply is an off-label use in the places that have published guidance on it.
My gynaec prescribed Domstal for supply. Should I stop it? Do not stop on your own. Ask the prescribing doctor about duration and review, since NHS guidance says regular review is needed if domperidone is used beyond 7 days, and stopping suddenly has its own reported problems.
Will it harm my baby? Infant exposure is very low — less than 0.1% of the maternal weight-adjusted dosage even at high maternal doses. The safety questions are about the mother's heart, not the milk.
What should I ask my doctor? Ask what the assessment found, what dose and for how many days, whether you have any cardiac or QT-affecting risk factors, and what the plan is for stopping. NHS guidance frames domperidone as something to consider only if a woman has no additional cardiac or medical risk factors and is not taking medication that interacts with domperidone or affects the QT interval.
Is a pill faster than seeing a lactation consultant? It feels faster. But the evidence base is small trials of pumped volume, and there is currently no evidence that use of domperidone improves breastfeeding outcomes. A latch assessment fixes the cause; the drug at best nudges the number.
